Table I.
Baseline patient and transplant characteristics, N=91.
| Variables | First HCT, N (%) | Second HCT, N (%) |
|---|---|---|
| Median age at HCT in years (range) | 43 (18–67) | 44 (18–73) |
| Males | 55 (60) | 48 (53) |
| Disease status at HCT | ||
| CR/CRi | 58 (64) | 56 (61) |
| Persistent disease | 29 (32) | 22 (24) |
| Unevaluable* | 4 (4) | 13 (15) |
| HCT Comorbidity index | ||
| 0–1 | - | 45 (49) |
| ≥2 | - | 46 (51) |
| Remission duration of first HCT, months (range) | 8.4 (1–70) | NA |
| Median time from first to second HCT, months (range) | NA | 14 (3–73) |
| Change in donors | NA | 48 (53) |
| Median calendar year of HCT (range) | 2009 (2000–2018) | 2010 (2000–2019) |
| Conditioning intensity | ||
| MAC (Bu>4000) | 61 (67) | 20 (22) |
| RIC/NMA | 30 (33) | 71 (78) |
| Bu<4000 | 5 (5) | 3 (3) |
| Mel | 23 (25) | 59 (65) |
| 100 | 4 (4) | 16 (18) |
| 140 | 19 (21) | 43 (47) |
| Other | 2 (3) | 9 (10) |
| Graft source | ||
| Peripheral blood | 51 (56) | 71 (78) |
| Bone marrow | 34 (37) | 19 (21) |
| Umbilical cord blood | 6 (7) | 1 (1) |
| Donor relation | ||
| Mismatched unrelated (cord) | 6 (7) | 1 (1) |
| Matched sibling donor | 42 (46) | 37 (41) |
| 10/10 Matched unrelated donor | 33 (36) | 32 (35) |
| 9/10 Matched unrelated donor | 4 (4) | 2 (2) |
| Mismatched family (haploidentical) | 6 (7) | 19 (21) |
| GVHD prophylaxis | ||
| Tacrolimus + MTX | 75 (82) | 63 (69) |
| PTCy +/− Tacrolimus +/− MMF | 15 (17) | 25 (28) |
| Other | 1 (1) | 3 (3) |
| Acute GVHD | 39 (43) | 44 (48) |
| Grade 2–4 | 18 (20) | 32 (35) |
| Grade 3–4 | 4 (4) | 13 (14) |
| Chronic GVHD | 17 (19)** | 25 (27) |
Abbreviations: HCT=hematopoietic cell transplantation; CR=complete response; CRi=complete response with incomplete hematologic recovery; MAC=myeloablative conditioning; RIC=reduced intensity conditioning; NMA=non-myeloablative conditioning; BU=busulfan; Mel=melphalan; GVHD=graft-versus-host disease; MTX=methotrexate; MMF=mycophenolate mofetil; PTCy=posttransplant cyclophosphamide.
*
Includes patients with 1) aplastic marrow insufficient for analysis and/or 2) patients who received a salvage treatment following the most recent disease evaluation.
**
Includes 9 patients with limited and 8 patients with extensive chronic GVHD.